8-K: Apyx Medical Reports Q1 2025 Results: Advanced Energy Revenue Up, Net Loss Decreases

Apyx Medical Corporation announced its first quarter 2025 financial results, highlighting growth in the Advanced Energy segment and a significant reduction in net loss.

Summary

• Apyx Medical Corporation reported a total revenue of $9.4 million for Q1 2025, a decrease from $10.2 million in the same period last year.
• However, Advanced Energy revenue increased by 6% to $7.9 million, driven by strong generator unit sales and U.S. single-use handpiece sales.
• OEM revenue decreased by 45% to $1.5 million.
• The net loss attributable to stockholders decreased by 45% to $4.2 million, compared to $7.6 million in Q1 2024.
• Adjusted EBITDA loss also decreased by 54% to $2.4 million.
• The company is preparing for the launch of the AYON Body Contouring System in the second half of 2025, pending FDA clearance.
• Apyx Medical reaffirmed its full-year 2025 revenue guidance of $47.6 million to $49.0 million.
• Operating expenses are expected to be less than $40.0 million for the year.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive due to the growth in the Advanced Energy segment, significant reduction in net loss and EBITDA loss, and reaffirmed financial guidance. However, the overall revenue decrease and OEM decline temper the optimism.

Positives

• Advanced Energy segment showed revenue growth of 6%.
• U.S. single-use handpiece revenue experienced a 14% increase.
• Net loss attributable to stockholders significantly decreased by 45%.
• Adjusted EBITDA loss decreased by 54%.
• Operating expenses are expected to be less than $40.0 million for the year ended December 31, 2025.
• Renuvion received the 2025 NewBeauty Award for Best Minimally Invasive Skin Tightener.
• The company is planning the launch of the AYON Body Contouring System in the second half of 2025, pending FDA clearance.

Negatives

• Total revenue decreased by 8% to $9.4 million compared to the same period last year.
• OEM revenue decreased significantly by 45%.
• Gross profit decreased to $5.7 million from $5.9 million in the prior year period.
• International revenue decreased 18%.

Risks

• The company is awaiting FDA clearance for the AYON Body Contouring System, and the launch is dependent on this approval.
• The company is monitoring the potential impact of trade policies and tariffs, which could affect product costs and gross margins.
• Decreases in sales volume to existing OEM customers, excluding Symmetry Surgical, impacted OEM revenue.
• The company acknowledges potential risks related to regulatory approvals, supply chain disruptions, economic conditions, and litigation.

Future Outlook

The company reaffirmed its financial guidance for full-year 2025, expecting total revenue in the range of $47.6 million to $49.0 million and operating expenses of less than $40.0 million.

Management Comments

• Charlie Goodwin, President and CEO, stated that Renuvion is positioned to be the standard-of-care for patients on GLP-1 drugs addressing loose skin post-weight loss.
• Mr. Goodwin also highlighted the positive feedback received for the AYON Body Contouring System at the Aesthetic MEET in March.
• Mr. Goodwin noted that cost-cutting measures implemented in Q4 of the previous year are reflected in the Q1 2025 financial results.

Industry Context

Apyx Medical is positioning itself as a leader in surgical aesthetics, particularly with Renuvion's potential in addressing skin laxity after weight loss, aligning with the growing popularity of GLP-1 drugs. The launch of AYON aims to provide a comprehensive solution for body contouring, potentially disrupting the market with its integrated features.

Comparison to Industry Standards

• Comparing Apyx Medical to companies like InMode or Cutera, which also operate in the aesthetic medical device market, Apyx's growth in the Advanced Energy segment is a positive sign.
• However, the decline in OEM revenue contrasts with the overall growth trend seen in the medical device manufacturing sector.
• The reduction in net loss and adjusted EBITDA loss indicates improved operational efficiency, aligning with industry benchmarks for companies focusing on profitability.

Stakeholder Impact

• Shareholders may view the reduced net loss and reaffirmed guidance positively.
• Employees may be affected by cost-cutting measures, but the company emphasizes its dedication to Apyx.
• Customers can anticipate the launch of the AYON system, offering a comprehensive body contouring solution.
• Suppliers may be impacted by changes in manufacturing locations and tariff policies.
• Creditors will likely view the improved financial performance favorably.

Next Steps

• The company plans to launch the AYON Body Contouring System in the second half of 2025, pending FDA clearance.
• The company will continue to monitor trade policies and tariffs to minimize their impact.
• The company will focus on executing its commercial strategy to drive long-term growth.

Key Dates

Keywords

Apyx Medical, Renuvion, AYON, Advanced Energy, OEM, Financial Results, Q1 2025, FDA Clearance, Body Contouring, Medical Devices